Results from Astra’s study found no one in the trial who received the cocktail contracted severe Covid-19 or died in relation to the disease, the company said in a statement on Friday. The trial of 5,197 participants, which started in November, was looking at whether the drug could prevent infection in at-risk groups and took place in the US, UK, Belgium, France and Spain.
from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/3CYXrWR
Home »
Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com
» AstraZeneca’s antibody drug prevents Covid-19 in high-risk groups: Study
https://ift.tt/eA8V8J
No comments:
Post a Comment